Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,093 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
10 practical priorities to prevent and manage serious allergic reactions: GA2LEN ANACare and EFA Anaphylaxis Manifesto.
Muraro A, de Silva D, Podesta M, Anagnostou A, Cardona V, Halken S, Smith P, Tanno LK, Turner P, Worm M, Alvaro-Lozano M, Arasi S, Asarnoj A, Barni S, Beyer K, Bilaver LA, Bird A, Bonaguro R, Brough HA, Chinthrajah RS, Cook EE, Demoulin C, Deschildre A, Dribin TE, Ebisawa M, Fernandez-Rivas M, Fiocchi A, Fleischer DM, Garrow E, Gerdts J, Giovannini M, Järvinen KM, Kelly M, Knol EF, Lack G, Lazzarotto F, Le TM, Leonard S, Lieberman J, Makris M, Mandelbaum L, Marchisotto MJ, Marino GA, Mori F, Nilsson C, Nowak-Wegrzyn A, Odemyr M, Oude Elberink HNG, Palosuo K, Patel N, Pier J, Poblete S, Rachid R, Rodríguez Del Río P, Said M, Sampson HA, Sánchez Sanz A, Schnadt S, Schultz F, Toniolo A, Upton JEM, Venter C, Vickery BP, Vlieg-Boerstra B, Wang J, Roberts G, Zuberbier T; GA2LEN ANACare Centres and EFA. Muraro A, et al. Among authors: nilsson c. Clin Transl Allergy. 2024 Dec;14(12):e70009. doi: 10.1002/clt2.70009. Clin Transl Allergy. 2024. PMID: 39614094 Free PMC article. Review.
GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management.
Zuberbier T, Muraro A, Nurmatov U, Arasi S, Stevanovic K, Anagnostou A, Bonaguro R, Chinthrajah S, Lack G, Fiocchi A, Le TM, Turner P, Lozano MA, Angier E, Barni S, Bégin P, Ballmer-Weber B, Cardona V, Bindslev-Jensen C, Cianferoni A, de Jong N, de Silva D, Deschildre A, Galvin AD, Ebisawa M, Fleischer DM, Gerdts J, Giovannini M, Gradman J, Halken S, Arshad SH, Khaleva E, Lau S, Loh R, Mäkelä MJ, Marchisotto MJ, Morandini L, Mortz CG, Nilsson C, Nowak-Wegrzyn A, Podestà M, Poulsen LK, Roberts G, Rodríguez Del Río P, Sampson HA, Sánchez A, Schnadt S, Smith PK, Szajewska H, Mitrevska NT, Toniolo A, Venter C, Warner A, Wong GWK, Wood R, Worm M. Zuberbier T, et al. Among authors: nilsson c. Clin Transl Allergy. 2024 Nov;14(11):e70002. doi: 10.1002/clt2.70002. Clin Transl Allergy. 2024. PMID: 39506193 Free PMC article. Review.
EAACI guidelines on the management of IgE-mediated food allergy.
Santos AF, Riggioni C, Agache I, Akdis CA, Akdis M, Alvarez-Perea A, Alvaro-Lozano M, Ballmer-Weber B, Barni S, Beyer K, Bindslev-Jensen C, Brough HA, Buyuktiryaki B, Chu D, Del Giacco S, Dunn-Galvin A, Eberlein B, Ebisawa M, Eigenmann P, Eiwegger T, Feeney M, Fernandez-Rivas M, Fiocchi A, Fisher HR, Fleischer DM, Giovannini M, Gray C, Hoffmann-Sommergruber K, Halken S, O'B Hourihane J, Jones CJ, Jutel M, Knol EF, Konstantinou GN, Lack G, Lau S, Mejias AM, Marchisotto MJ, Meyer R, Mortz CG, Moya B, Muraro A, Nilsson C, de Oliveira LCL, O'Mahony L, Papadopoulos NG, Perrett KP, Peters R, Podesta M, Poulsen LK, Roberts G, Sampson H, Schwarze J, Smith P, Tham E, Untersmayr E, Van Ree R, Venter C, Vickery B, Vlieg-Boerstra B, Werfel T, Worm M, Du Toit G, Skypala I. Santos AF, et al. Among authors: nilsson c. Allergy. 2025 Jan;80(1):14-36. doi: 10.1111/all.16345. Epub 2024 Oct 30. Allergy. 2025. PMID: 39473345 Free PMC article.
Characterization of exposure to air pollutants for workers in and around fires.
Lovén K, Hagvall L, Rex J, Nilsson CA, Malmborg V, Pagels J, Strandberg B, Hedmer M. Lovén K, et al. Among authors: nilsson ca. J Occup Environ Hyg. 2024 Dec;21(12):878-894. doi: 10.1080/15459624.2024.2406244. Epub 2024 Oct 17. J Occup Environ Hyg. 2024. PMID: 39418654 Free article.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
1,093 results